Cough syrup is a medication used to relieve symptoms of cough, including dry cough or a cough with phlegm. It typically contains one or more active ingredients such as dextromethorphan, codeine, or guaifenesin, along with other inactive ingredients like flavoring agents, sweeteners, and preservatives.
Dextromethorphan is a cough suppressant that works by reducing the activity of the cough reflex in the brain. Codeine is also a cough suppressant, but it is a narcotic that can be addictive and is usually only available with a prescription. Guaifenesin is an expectorant that thins the mucus in the airways, making it easier to cough up.
Request Report Sample-https://www.alliedmarketresearch.com/request-sample/10677
Cough syrup is usually taken orally in liquid form and can
be purchased over the counter or with a prescription from a healthcare
provider. It is important to follow the instructions on the label or given by a
healthcare provider, as cough syrup can cause side effects such as drowsiness,
dizziness, and nausea. It is also important to only use cough syrup for the
recommended period of time, as prolonged use can lead to dependence or other
health problems.
The global cough syrup market was valued at $5,232.73
million in 2019, and is projected to reach $6,108.25 million by 2027,
registering a CAGR of 2.8% from 2020 to 2027.
Covid-19 scenario-
• The
corona virus outbreak has had a mixed impact on the global cough syrup market.
The sale for cough syrup primarily took a leap, as this over-the-counter drug
has been widely used for patients with sneezing, common cold, runny nose, and
other respiratory allergies.
• However,
a new research paper published in the journal Nature found that
dextromethorphan might intensify the replication of SARS-CoV-2, the virus that
causes COVID-19. A cough syrup ingredient has pro-viral properties and as per
scientists, it should be avoided by people infected by the covid-19 virus.
• Simultaneously,
the manufacturers happened to face several challenges related to high cost of
raw materials and shortage of supply during the lockdown.
Procure Complete Report (220 Pages PDF with Insights,
Charts, Tables, and Figures) @ Buy-now
By region, Asia-Pacific accounted for the largest share of
revenue in 2019, and is anticipated to maintain its dominance from 2020 to 2027
due to easier availability of cough syrups at retail pharmacies, rise in
geriatric population, and less stricter laws regarding the abuse of cough &
cold medicines in the region. However, LAMEA is expected to register the highest
CAGR during the forecast period as governments are investing in the development
of healthcare infrastructure and increasing cases of respiratory disorder.
The report provides some of the key players operating in the
cough syrup market such as Novartis AG, Pfizer, Inc., Merck KGaA,
GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Acella
Pharmaceuticals, LLC, Reckitt Benckiser Group PLC, Sanofi, Procter &
Gamble, and Abbott Laboratories. The other players (not profiled in the report)
in the value chain include Sun Pharmaceutical Industries, Shanghai
Pharmaceutical, AstraZaneca, and others.
Speak to our Analyst -
https://www.alliedmarketresearch.com/connect-to-analyst/10677
Know more- https://www.alliedmarketresearch.com/cough-syrup-market-A10312
Related Reports-
Bovine Mastitis Market-
https://www.alliedmarketresearch.com/bovine-mastitis-market-A17539
Medical Tape Market
- https://www.alliedmarketresearch.com/medical-tape-market-A17081
